NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $46.60 -4.36 (-8.56%) Closing price 04:00 PM EasternExtended Trading$48.50 +1.90 (+4.09%) As of 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About PTC Therapeutics Stock (NASDAQ:PTCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$46.37▼$51.4350-Day Range$45.08▼$57.1752-Week Range$24.00▼$58.38Volume2.88 million shsAverage Volume791,882 shsMarket Capitalization$3.68 billionP/E RatioN/ADividend YieldN/APrice Target$63.77Consensus RatingModerate Buy Company OverviewPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More… Remove Ads PTC Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScorePTCT MarketRank™: PTC Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 230th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 8 buy ratings, 4 hold ratings, and 2 sell ratings.Amount of Analyst CoveragePTC Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -7.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PTC Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.90% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.38 Percentage of Shares Shorted5.90% of the float of PTC Therapeutics has been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 13.46%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.43 News SentimentPTC Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.Search Interest2 people have searched for PTCT on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,799,047.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesStephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockMarch 18, 2025 | insidertrades.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 1,230 SharesMarch 7, 2025 | insidertrades.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.April 1, 2025 | Brownstone Research (Ad)PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On TranslarnaMarch 30 at 10:46 AM | nasdaq.comPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2025 | prnewswire.comPTC Therapeutics says European Commission will remove muscle disorder drugMarch 28, 2025 | reuters.comPTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in EuropeMarch 28, 2025 | prnewswire.comFirst Week of May 16th Options Trading For PTC TherapeuticsMarch 26, 2025 | nasdaq.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $45.14 at the beginning of the year. Since then, PTCT stock has increased by 3.2% and is now trading at $46.60. View the best growth stocks for 2025 here. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.54) by $0.15. The biopharmaceutical company had revenue of $196.79 million for the quarter, compared to analyst estimates of $173.51 million. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD). Company Calendar Last Earnings11/07/2024Today4/01/2025Next Earnings (Estimated)4/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Target$63.77 High Stock Price Target$113.00 Low Stock Price Target$42.00 Potential Upside/Downside+28.9%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($4.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-50.32% Pretax Margin-47.24% Return on EquityN/A Return on Assets-16.44% Debt Debt-to-Equity RatioN/A Current Ratio2.10 Quick Ratio2.04 Sales & Book Value Annual Sales$806.78 million Price / Sales4.83 Cash Flow$2.38 per share Price / Cash Flow20.80 Book Value($10.85) per share Price / Book-4.56Miscellaneous Outstanding Shares78,869,000Free Float72,883,000Market Cap$3.90 billion OptionableOptionable Beta0.66 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:PTCT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.